Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
Oracle Corporation's cloud ERP for SMBs (40,000+ customers, 219 countries); NetSuite Next's Ask Oracle natural language AI assistant (SuiteWorld 2025), single-platform financial/CRM/inventory competing with SAP Business One.
NetSuite is a San Mateo, California and Austin, Texas-based cloud enterprise resource planning (ERP) platform and business unit of Oracle Corporation (NYSE: ORCL) — serving over 40,000 customers in 219 countries and territories with cloud-native financial management, CRM, inventory, supply chain, human capital management, and e-commerce applications designed for small-to-midsize businesses and rapidly growing enterprises that need unified business management software from a single cloud platform. NetSuite was founded in 1998 as NetLedger (one of the world's first cloud-based ERP systems) and acquired by Oracle in 2016 for $9.3 billion. Oracle's platform integration — connecting NetSuite to Oracle Cloud Infrastructure (OCI), Oracle Analytics Cloud, and Oracle's AI layer — enables NetSuite to leverage hyperscale compute, data warehousing, and generative AI capabilities that independent ERP vendors cannot build at equivalent cost. At SuiteWorld 2025, NetSuite unveiled NetSuite Next, featuring Ask Oracle — a natural language AI assistant enabling business users to search records, navigate workflows, analyze financial data, and trigger business actions across the entire NetSuite dataset through conversational queries rather than menu navigation — advancing toward autonomous AI-driven business management. The Oracle leadership transition (co-CEOs Clay Magouyrk and Mike Sicilia replacing Safra Catz) underscores Oracle's commitment to accelerating cloud product innovation across NetSuite, Oracle Cloud ERP (Fusion), and Oracle's SaaS portfolio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.